Overview

Velcade for Proliferative Lupus Nephritis

Status:
Withdrawn

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

The primary objective is to test the safety and efficacy of Velcade to induce remission in WHO class III/IV/V lupus nephritis that are refractory to standard medications.

Phase:

Phase 4

Details

Lead Sponsor:

The Rogosin Institute

Collaborator:

Weill Medical College of Cornell University

Treatments:

Bortezomib
Proteasome Inhibitors